Current Oncology (Nov 2022)

Gastroblastoma Treated by Endoscopic Submucosal Excavation with a Novel <i>PTCH1::GLI2</i> Fusion: A Rare Case Report and Literature Review

  • Yongru Liu,
  • Huanwen Wu,
  • Xi Wu,
  • Yunlu Feng,
  • Qingwei Jiang,
  • Qiang Wang,
  • Aiming Yang

DOI
https://doi.org/10.3390/curroncol29110697
Journal volume & issue
Vol. 29, no. 11
pp. 8862 – 8873

Abstract

Read online

Gastroblastoma is an extremely rare stomach tumor that primarily presents in adolescent and early adulthood, with a biphasic cell morphology of epithelioid and spindle cells. In light of its similarity to other childhood blastomas, it has been named gastroblastoma. Few patients showed a potential of metastasis and recurrence, however, most of the reported cases were alive, with no evidence of the disease after surgical treatment. Commonly, MALAT1-GLI1 fusion has been considered to be the most relevant mutation. Herein, we present a case of an asymptomatic 58-year-old man who happened to find a submucosal gastric mass during a gastroscope and received endoscopic submucosal excavation (ESE). He turned out to have a gastroblastoma with a novel PTCH1::GLI2 fusion confirmed by Sanger sequencing. The patient was discharged two days after ESE without any complication and was recurrence-free during his one-year follow-up. According to the previous literature and our own experience, in cases with characteristic histopathology and immunohistochemistry patterns, a diagnosis of gastroblastoma should be considered even without a MALAT1-GLI1 fusion. Gastroblastoma pursues a favorable clinical outcome and endoscopic therapy could be an effective alternative treatment choice.

Keywords